{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Tseng H"],"pubmed_abstract":["Autologous CAR-T therapies targeting B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma (RRMM) have demonstrated therapeutic clinical responses. Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a T<sub>SCM</sub>-predominant allogeneic CAR-T therapy targeting BCMA in heavily pretreated relapsed/refractory multiple myeloma. Preclinical analyses reveal a strong correlation between CD8<sup>+</sup> T<sub>SCM</sub> phenotype and in vivo potency in mouse xenograft models. In early clinical data (NCT04960579), among the 11 of 33 evaluable patients who received enhanced lymphodepletion, 82% (9/11) responded, with 63.6% (7/11) achieving very good partial response (VGPR) or better. All patients started therapy a median of 1 day after enrollment, w"],"journal":["Nature communications"],"pagination":["10050"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12644732"],"repository":["biostudies-literature"],"pubmed_title":["T&lt;sub&gt;SCM&lt;/sub&gt;-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial."],"pmcid":["PMC12644732"],"pubmed_authors":["Namini H","Shune L","Kin A","McCaigue J","Richter M","Marquez KS","Solimine B","Tseng H","Eskew JD","Haag S","Kwong J","Martin CE","McArthur K","Coffey MJ","Cranert SA","Cho BS","Shedlock DJ","Krasny A","Ramakrishnan A","Bacong A","Costello CL","Coronella J","Kocoglu MH","Loyola A","Dholaria B","Belani R"],"additional_accession":[]},"is_claimable":false,"name":"T&lt;sub&gt;SCM&lt;/sub&gt;-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.","description":"Autologous CAR-T therapies targeting B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma (RRMM) have demonstrated therapeutic clinical responses. Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a T<sub>SCM</sub>-predominant allogeneic CAR-T therapy targeting BCMA in heavily pretreated relapsed/refractory multiple myeloma. Preclinical analyses reveal a strong correlation between CD8<sup>+</sup> T<sub>SCM</sub> phenotype and in vivo potency in mouse xenograft models. In early clinical data (NCT04960579), among the 11 of 33 evaluable patients who received enhanced lymphodepletion, 82% (9/11) responded, with 63.6% (7/11) achieving very good partial response (VGPR) or better. All patients started therapy a median of 1 day after enrollment, w","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-06T15:46:40.132Z","creation":"2026-06-02T03:09:33.197Z"},"accession":"S-EPMC12644732","cross_references":{"pubmed":["41285709"],"doi":["10.1038/s41467-025-65267-0"]}}